Related Experiment Video
Updated: Aug 30, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
[Modified FLAG regimen in the management of refractory acute myeloid leukemia]
Long-jiang Yang1, Fan-yi Meng, Bing Xu
1Department of Hematology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China. yanglongjiang@hotmail.com
Objective:
To evaluate the therapeutic effect of modified FLAG regimen in the management of refractory acute myeloid leukemia (AML).
Methods:
Sixteen patients with refractory AML were divided into two groups. In modified FLAG regimen group (n=10), the patients received fludarabine (Flu, 50 mg/d, VDx5 d) and Ara-c (200 mg/d, VDx5 or 7 d). The regimen for classic FLAG group (n=6) consisted of Flu (50 mg/d, VDx5d), Ara-C (500 or 1,000 mg/d, VDx5d) and G-CSF (300 microg/d, x5 d, subcutaneously injected 4-6 hours before chemotherapy). Each patient received subcutaneous G-CSF (300 microg/d) when the white blood cell count was lower than 1.0x10(9)/L till the condition was corrected.
Results:
The total complete remission(CR) rate of the 16 patients was 50% (8/16). Seven patients in modified group achieved CR (70%) and only one of the classic group did (17%, P<0.05). Episodes of infections were lower in modified group than in the classic group (50% vs 83%).
Conclusion:
Modified FLAG regimen is more likely than classic FLAG regimen to achieve CR and reduce infections in patients with refractory AML.